Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Region Hovedstadens forskningsportal Forside
Hjælp og OSS
Dansk
English
Forside
Hospitaler/afdelinger
Forskere
Publikationer
Aktiviteter
Priser
Søg efter ekspertise, navn eller tilknytning
Nils Hoyer
Reservelæge
,
Herlev og Gentofte Hospital
,
Lungemedicinsk afd
Herlev og Gentofte Hospital
,
Medicinske Sygdomme
Amager og Hvidovre Hospital
,
Lungemedicinsk og endokrinologisk Afdeling
https://orcid.org/0000-0003-4395-1837
2018
2024
Publikationer pr. år
Vis
Fingeraftryk
Netværk
Publikationer
(23)
Priser
(1)
Lignende profiler
(6)
Fingeraftryk
Dyk ned i forskningsemnerne, hvor Nils Hoyer er aktive. Disse emneetiketter kommer fra dennes persons arbejder. Sammen danner de et unikt fingerprint.
Sorter
Vægt
Alfabetisk
Medicine and Dentistry
Idiopathic Pulmonary Fibrosis
83%
Interstitial Lung Disease
35%
Biological Marker
31%
Chronic Obstructive Pulmonary Disease
25%
St. George Respiratory Questionnaire
20%
Disease
19%
Collagen Type 6
17%
Quality of Life
17%
Lung Cancer
16%
Lung Cancer Screening
16%
Diagnostic Delay
16%
Respiratory Failure
16%
Smoking
16%
Infection
16%
Disease Exacerbation
16%
Severe Acute Respiratory Syndrome Coronavirus 2
14%
Six Minute Walk Test
13%
Fibrosis
12%
Arm
12%
Cohort Analysis
12%
Dyspnea
10%
Medicine
9%
Minimal Clinically Important Difference
9%
Collagen Type 3
9%
Hydroxychloroquine
8%
Hypoxia
8%
Respiratory Disease
8%
Collagen Type 1
8%
Retrospective Cohort Study
8%
Progression Free Survival
8%
Hyperbarism
8%
Positive Airway Pressure
8%
COVID-19
8%
Chronic Disease
8%
Respiratory System Disease
8%
Fibroblast
8%
Noninvasive Ventilation
8%
Intervention Study
8%
Nicotine Withdrawal
8%
Lactate Dehydrogenase
8%
Hazard Ratio
7%
All Cause Mortality
6%
Progressive Disease
6%
Extracellular Matrix
6%
Proportional Hazards Model
5%
Cancer
5%
Patient-Data
5%
Heart Failure
5%
Keyphrases
Idiopathic Pulmonary Fibrosis
100%
St. George's Respiratory Questionnaire
29%
Collagen Turnover
18%
King's Brief Interstitial Lung Disease Questionnaire
18%
Type VI Collagen
17%
Disease Progression
17%
Diagnostic Delay
16%
Interstitial Lung Abnormalities
16%
Type III Collagen
16%
Chronic Obstructive Pulmonary Disease
16%
Antifibrotic
14%
Quality of Life
13%
PRO-C6
12%
PRO-C3
11%
Real-life Cohort
11%
Hazard Ratio
10%
Fibrosis Score
10%
Smokers
10%
Dyspnea
10%
Disease Severity
9%
Comorbidity
9%
Increased Mortality
9%
Pirfenidone
9%
Nintedanib
9%
Hospitalization Rate
9%
Improved Survival
9%
Low Intensity
9%
Minimal Clinically Important Difference
9%
Delayed Diagnosis
8%
Endotrophin
8%
Silent Hypoxia
8%
Physiological Parameters
8%
Fibroblasts
8%
Chronic Disease
8%
Clinical Parameters
8%
Expiratory Positive Airway Pressure
8%
Sars-cov-2 Infection
8%
Progression-free Survival
8%
Quality of Survival
8%
AE-ILD
8%
AE-IPF
8%
High Turnover
8%
Extracellular Matrix Remodeling
8%
Hydroxychloroquine
8%
Study within a Trial
8%
Lactate Dehydrogenase
8%
Acute Exacerbation
8%
Tobacco
8%
Retrospective Cohort Study
8%
Hospital Discharge
8%
